Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

other Versions

You are currently viewing an earlier version of this article (February 21, 2022).
View the most recent version of this article

Commentary

Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

Online download statistics by month:

Online download statistics by month: March 2022 to March 2023

	Abstract	Full	Pdf
Feb 2022	0	16	15
Mar 2022	0	20	11
Apr 2022	0	14	16
May 2022	0	14	13
Jun 2022	0	9	11
Jul 2022	0	8	7
Aug 2022	0	7	2
Sep 2022	0	4	2
Oct 2022	0	8	1
Nov 2022	0	4	15
Dec 2022	0	3	2
Jan 2023	0	7	2
Feb 2023	0	6	1
Mar 2023	0	9	5
Total	0	129	103